understanding biosimilars
Published 7 years ago • 60 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
2:43
why do we need biosimilars?
-
1:32
the regulation of biosimilars
-
5:28
the potential impact of biosimilars in hematology
-
1:42
advantages of using biosimilars
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:34
bios human: what is melanopsin?
-
3:18
what is a biosimilar, exactly?
-
3:00
biosimilars: complex copycat drugs
-
1:52
biosimilars - the question of trials and approval
-
38:15
biosimilars and biologics
-
1:12
insights into the optimal management of cll: the importance of patient characteristics
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
4:12
the basics of biosimilars
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
2:34
the impact of ethnicity on biomarker-based staging in al amyloidosis
-
4:38
phase i study of neihulizumab in patients with sr-agvhd or tr-agvhd
-
1:00:51
biosimilars explained: what patients need to know
-
1:48
dr. markman on the concept of biosimilars in oncology
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:57
post-hoc analysis of optic: patient responses to ponatinib by t315i mutational status
-
1:32
post hoc analysis of optic: patient responses by t315i mutation status
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial